Study of Dextromethorphan in OCD and Related Disorders

Recruiting now · Phase 2

Conditions studied: Obsessive-Compulsive Disorder, Illness Anxiety Disorder, Body Dysmorphic Disorders, Somatic Symptom Disorder

In brief

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Key facts

Study ID

NCT04899687

Run by

Stanford University

People needed

60

Starts

2022-01-20

Expected to finish

2028-12-01

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
• Living within California
• Capacity to provide informed consent

You may not qualify if…

• Current bipolar disorder or psychotic disorder
• Active moderate or severe substance use disorder, lifetime severe substance use disorder
• Pregnant or nursing women
• Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
• Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start

Where it is running

• Stanford University — Stanford, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.